ChemoCentryx selects Amber Specialty Pharmacy to dispense Tavneos

Tavneos is used as an adjunctive treatment of adult patients with severe active ANCA-associated vasculitis, in combination with standard therapy.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Amber Specialty Pharmacy will begin dispensing Tavneos (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis), in combination with standard therapy.

Tavneos is manufactured by California-based ChemoCentryx, a biopharma company focused primarily on orphan and rare diseases.

ANCA-associated vasculitis is a rare systemic disease in which over-activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney as the major target, and is fatal if not treated.

[Read more: Retailers build out their specialty offerings]

Through this partnership, Amber Specialty Pharmacy's best-in-class service model will support autoimmune specialists, rheumatologists and patients throughout the country. Amber Specialty Pharmacy is one of two specialty pharmacies selected by ChemoCentryx to dispense Tavneos as part of a limited distribution network.

"Being selected to care for the ANCA-associated vasculitis population, to us, is validation of the extraordinary services and compassionate care we bring to the rare disease patient populations," said Kristin Williams, president of Amber Specialty Pharmacy. "We are honored to partner with ChemoCentryx to improve quality of care and deliver meaningful results and outcomes for vasculitis patients.”